Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis
The Oncologist · 08.07.2026 · 31 (8)
DOI: 10.1093/oncolo/oyag270 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 14.07.2026. Verfasst von Federico Nichetti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, 35128, Italy. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Background
First-line treatment of HER2-positive advanced gastric/GEJ adenocarcinoma now includes pembrolizumab added to trastuzumab plus chemotherapy (KEYNOTE-811). Zanidatamab, a bispecific anti-HER2 antibody, improved outcomes in HERIZON-GEA-01 but has not been directly compared with this standard.
Methods
We searched PubMed, Scopus, and the ASCO/ESMO libraries for phase II/III trials of previously untreated HER2-positive metastatic gastric/GEJ adenocarcinoma. Individual patient data were reconstructed from published Kaplan-Meier curves. Cox frailty models estimated hazard ratios using the pembrolizumab regimen as the reference. Restricted mean survival time analysis was performed at 12, 24, and 36 months.
Results
Nine trials were included: trastuzumab + chemotherapy (n = 1466), pembrolizumab + trastuzumab + chemotherapy (n = 430), zanidatamab + chemotherapy (n = 350), and zanidatamab + tislelizumab + chemotherapy (n = 335). Median PFS was 12.5 months with both zanidatamab regimens vs 10.0 months with pembrolizumab. The zanidatamab-tislelizumab triplet significantly reduced progression hazard (HR, 0.78, 95% CI, 0.62-0.99; P = 0.042). Median OS was 27.0 and 25.3 months with zanidatamab arms vs 20.3 months with pembrolizumab. Both zanidatamab arms showed significantly longer OS at 36 months by RMST.
Conclusions
Zanidatamab-based regimens were associated with longer PFS and OS than the pembrolizumab standard, though direct randomized comparisons are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, 35128, Italy.
- Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, 35122, Italy.
ORCID-Profile: Federico Nichetti, Floriana Nappo
Förderung
- Italian Ministry of Health
Zitieren
APA
Nichetti, F., Nappo, F., Bof, F., Bosa, M., Mattiuzzo, E., Maddalena, G., De Grandis, M. C., Murgioni, S., Bergamo, F., & Lonardi, S. (2026). Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag270
Vancouver
Nichetti F, Nappo F, Bof F, Bosa M, Mattiuzzo E, Maddalena G, et al. Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag270
BibTeX
@article{Nichetti2026,
author = {Nichetti, Federico and Nappo, Floriana and Bof, Francesca and Bosa, Martina and Mattiuzzo, Elena and Maddalena, Giulia and De Grandis, Maria Caterina and Murgioni, Sabina and Bergamo, Francesca and Lonardi, Sara},
title = {Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {8},
doi = {10.1093/oncolo/oyag270}
}
EUVIMED